Renaissance United Limited (SGX:I11)

Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions SGD. Fiscal year is May - April.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 8, 2025	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021
Market Capitalization	6	6	6	6	12	19
Market Cap Growth	-	-	-	-50.00%	-33.33%	200.00%
Enterprise Value	24	24	36	33	37	47
PS Ratio	0.08	0.08	0.07	0.08	0.16	0.24
PB Ratio	0.27	0.27	0.17	0.13	0.21	0.27
P/FCF Ratio	-	-	2.46	-	40.14	2.01
P/OCF Ratio	-	-	2.28	-	21.84	1.99
EV/Sales Ratio	0.31	0.31	0.38	0.44	0.49	0.61
EV/EBITDA Ratio	171.79	169.59	4.05	12.87	8.63	4.77
EV/EBIT Ratio	-	-	7.02	-	-	9.73
EV/FCF Ratio	-9.65	-	14.14	-	118.85	5.06
Debt / Equity Ratio	1.00	1.00	0.71	0.48	0.38	0.33
Debt / EBITDA Ratio	161.53	161.53	2.82	7.52	4.77	2.24
Debt / FCF Ratio	-	-	10.27	-	71.98	2.47
Quick Ratio	0.57	0.57	0.57	0.51	0.52	0.58
Current Ratio	0.59	0.59	0.70	0.76	0.72	0.76
Asset Turnover	0.94	0.94	0.98	0.68	0.61	0.58
Return on Equity (ROE)	-42.22%	-42.22%	-23.79%	-15.23%	-19.44%	-6.90%
Return on Assets (ROA)	-3.28%	-3.28%	3.33%	-0.85%	-0.55%	2.27%
Return on Capital (ROIC)	-5.03%	-5.03%	4.82%	-1.24%	-0.79%	3.19%
Return on Capital Employed (ROCE)	-	-	10.90%	-	-	5.90%
Earnings Yield	-139.37%	-139.37%	-109.73%	-98.01%	-99.41%	-29.13%
Earnings Yield	-139.37%	-139.37%	-109.73%	-98.01%	-99.41%	-29.13%
FCF Yield	-40.33%	-40.34%	40.69%	-62.68%	2.49%	49.85%

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Utility template. Financial Sources.